ImmunityBio (IBRX) Convertible Debt (2022 - 2026)
ImmunityBio (IBRX) posted quarterly Convertible Debt of $678.4 million for Q1 2026, up 39.67% year-over-year from $485.7 million in Q1 2025, and up 42.19% quarter-over-quarter from $477.1 million in Q4 2025.
ImmunityBio (IBRX) Convertible Debt (2022 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Convertible Debt for 5 consecutive years, with $678.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Convertible Debt rose 39.67% year-over-year to $678.4 million; the TTM figure through Mar 2026 stood at $678.4 million (up 39.67% YoY), while the FY2025 annual figure was $477.1 million, up 3.29% from the prior year.
- Convertible Debt improved to $678.4 million in Q1 2026 per IBRX's latest filing, from $477.1 million in the prior quarter.
- Across five years, Convertible Debt topped out at $678.4 million in Q1 2026 and bottomed at $165.3 million in Q3 2023.
- Historically, Convertible Debt has averaged $467.9 million across 5 years, with a median of $492.1 million in 2025.
- On a YoY basis, Convertible Debt climbed as much as 255.73% in 2024 and fell as far as 19.95% in 2024.
- ImmunityBio's Convertible Debt stood at $241.3 million in 2022, then jumped by 139.13% to $577.0 million in 2023, then dropped by 19.95% to $461.9 million in 2024, then climbed by 3.29% to $477.1 million in 2025, then surged by 42.19% to $678.4 million in 2026.
- Business Quant data shows IBRX's Convertible Debt at $678.4 million in Q1 2026, $477.1 million in Q4 2025, and $500.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 774.35 Mn |
| Mar 31, 2026 | 678.39 Mn |
| Dec 31, 2025 | 477.09 Mn |
| Sep 30, 2025 | 500.80 Mn |
| Jun 30, 2025 | 492.08 Mn |
| Mar 31, 2025 | 485.72 Mn |
| Dec 31, 2024 | 461.88 Mn |
| Sep 30, 2024 | 587.98 Mn |
| Jun 30, 2024 | 584.11 Mn |
| Mar 31, 2024 | 580.45 Mn |
| Dec 31, 2023 | 576.95 Mn |
| Sep 30, 2023 | 165.29 Mn |
| Jun 30, 2023 | 250.10 Mn |
| Dec 31, 2022 | 241.27 Mn |